Asset Details
Do you wish to reserve the book?
26 What drives rapid progression to ESRD in patients with lupus nephritis?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
26 What drives rapid progression to ESRD in patients with lupus nephritis?
Do you wish to request the book?
26 What drives rapid progression to ESRD in patients with lupus nephritis?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
26 What drives rapid progression to ESRD in patients with lupus nephritis?
2022
Overview
Lupus nephritis (LN) affects up to 40% of patients with systemic lupus erythematosus (SLE) and leads to end stage kidney disease (ESRD) in 17–33% after 10 years.1 We have investigated a number of factors that have been shown to predispose to a more rapid progression to ESRD, including time to initial response to conventional therapy, number of flares during follow-up, duration of immunosuppressive therapy, unusual histologic patterns and patient compliance.In the Toronto Lupus Cohort of 418 patients with LN, 209 (50%) achieved remission within the first year from LN diagnosis, 102 (24.4%) within the 2nd and 3rd years, 70 (16.7%) after 3 years and 37 (8.9%) never achieved remission. Sixty-six patients (15.8%) developed advanced chronic kidney disease after 9.5 years on average. The 66 patients who progressed to ESRD had a longer time to complete remission (3.0 ± 3.4 vs 1.6 ± 2.1 yrs), more often had two or more flares (40 (60.6%) vs 117 (33.2%) and had a shorter median time on immunosuppressants from complete remission to outcome (2 yrs (0–7) versus 4 yrs (0–8)). These factors remained independently significant in a multivariable analysis accounting for multiple other relevant factors.Catastrophic progression to ESRD was also associated with unusual histologic patterns. Examples of these included thrombotic microangiopathy, interstitial inflammation added to the classic ISN classes, collapsing glomerulopathy, concomitant anti-GBM nephropathy and poor patient compliance.These findings emphasize the importance of achieving early remission as well as flare prevention with prolonged immunosuppressive use and attention to patient compliance to maximise renal survival in LN.ReferenceTektonidou MG, et al. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol 2016 Jun;68(6):1432–1441.Learning ObjectivesExplain that shorter time to remission of LN protects against rapid progression to ESRDExplain that preventing flares in LN protects against rapid progression to ESRDExplain that longer duration of immunosuppressive therapy in LN protects against rapid progression to ESRDDescribe the unusual features of LN that might lead to catastrophic progression to ESRD
Publisher
Lupus Foundation of America,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
